Phenylephrine

證據等級: L5

預測適應症: 3 個

Phenylephrine: From Decongestant/Vasoconstrictor Use to Nasal Cavity Disease

One-Sentence Summary

Phenylephrine is an α1-adrenergic receptor agonist already used pharmacologically as a nasal and ocular decongestant/vasoconstrictor, though no formal original-indication or Finland market-authorization record is present in this evidence pack. The TxGNN model predicts it may be effective for Nasal Cavity Disease, with 8 clinical trials and 8 publications currently identified — but most of this evidence concerns phenylephrine-containing combination products (e.g., co-phenylcaine, Polydexa) or comparator decongestants (oxymetazoline, xylometazoline, cocaine) rather than phenylephrine monotherapy tested directly against this indication.

Quick Overview

Item	Content
Original Indication	Not available — phenylephrine holds no license record in this dataset (0 Finland authorizations); pharmacologically known as a nasal/ocular decongestant and vasoconstrictor
Predicted New Indication	Nasal Cavity Disease
TxGNN Prediction Score	99.97% (rank 534)
Evidence Level	L3
Finland Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed original mechanism-of-action data was not supplied for this drug (flagged as a High-severity data gap, DG002). However, the evidence pack's own rationale confirms phenylephrine is an α1-adrenergic receptor agonist whose classic pharmacology is nasal mucosal vasoconstriction and decongestion — this is an established mechanism, not a novel repurposing hypothesis.

Because this mechanism is already the textbook basis for nasal decongestant use, the TxGNN prediction of "Nasal Cavity Disease" largely reconfirms known pharmacology rather than surfacing an unexpected new indication. Supporting evidence mostly comes from phenylephrine-containing combination products used peri-procedurally (co-phenylcaine, Polydexa with phenylephrine) or from trials comparing alternative decongestants (oxymetazoline, xylometazoline, epinephrine, cocaine) for nasal mucosal shrinkage before endoscopy or sinus surgery — supporting the mechanistic class effect, though direct phenylephrine-monotherapy RCTs against a defined nasal cavity disease endpoint are limited.

Given the absence of both a documented original indication and TFDA/national package-insert safety data (DG001, Blocking severity), the mechanistic plausibility should be treated as reinforcing rather than establishing a new therapeutic claim.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03380715	NA	Completed	106	Co-phenylcaine (phenylephrine + lidocaine) nasal spray vs. nasal nebulization for decongestion/local anesthesia before rigid nasoendoscopy
NCT03228914	Phase 4	Completed	20	Compared 0.05% oxymetazoline vs. 1:1000 epinephrine (not phenylephrine) for blood loss/visualization before endoscopic sinus surgery
NCT02993770	NA	Unknown	120	Endonasal-endoscopic vs. external dacryocystorhinostomy for nasolacrimal duct obstruction; no phenylephrine arm specified
NCT00562120	Phase 2	Completed	21	Double-blind crossover RCT of an H3-antagonist on nasal congestion after allergen challenge in seasonal allergic rhinitis
NCT06457100	Phase 1/2	Active, not recruiting	60	IV esmolol vs. lidocaine for postoperative recovery quality after functional endoscopic sinus surgery
NCT04104789	Phase 2	Withdrawn	0	Kovanaze (tetracaine + oxymetazoline) nasal mist vs. articaine for maxillary pulpal anesthesia; withdrawn, no enrollment
NCT06443255	Phase 3	Completed	16	Cocaine vs. lidocaine/xylometazoline vs. saline for intranasal analgesia before awake nasotracheal intubation; no phenylephrine arm
NCT03962634	Phase 2	Terminated	3	Same Kovanaze vs. articaine design as NCT04104789; terminated early, minimal enrollment

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15854186	2005	RCT	International Journal of Clinical Practice	Double-blind RCT: cophenylcaine spray vs. placebo before flexible nasendoscopy — no significant difference in pain/discomfort
25133491	2014	RCT (indirect comparator)	PLoS ONE	Triple-blind RCT of topical tranexamic acid on bleeding/surgical field quality during FESS
40899890	2025	Experimental + Clinical	Vestnik Otorinolaringologii	Safety/efficacy evaluation of Polydexa spray with phenylephrine in acute rhinosinusitis
37184554	2023	Review	Vestnik Otorinolaringologii	Differential diagnosis of chronic nasal disease after surgery and topical antibiotic therapy, including Polydexa with phenylephrine
37970776	2023	Review	Vestnik Otorinolaringologii	Pathogenetic approach to treating inflammatory diseases of the nose and paranasal sinuses
9780066	1998	Cohort	International Journal of Pediatric Otorhinolaryngology	Acoustic rhinometry of nasal cavity/nasopharynx geometry after adenotonsillectomy
7378007	1980	Case Report	Archives of Ophthalmology	Cocaine toxicity during dacryocystorhinostomy; one patient also reacted to intranasal phenylephrine
1375136	1992	In Vitro	Clinical Otolaryngology and Allied Sciences	Preliminary in vitro study of drug effects on nasal ciliary beat frequency

Finland Market Information

Phenylephrine currently has no marketing authorization on record in Finland (market status: 未上市 / Not marketed; 0 authorizations). No product-level license data is available to summarize.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The predicted indication is consistent with phenylephrine's established α1-agonist decongestant pharmacology and is corroborated by several trials/publications, but nearly all of this evidence involves combination products or comparator decongestants rather than phenylephrine monotherapy tested directly for a defined nasal cavity disease endpoint — evidence level L3. Combined with the Blocking-severity absence of package-insert warnings/contraindications, a cautious, guardrailed path is warranted rather than a full Go.

To proceed, the following is needed:

TFDA/national package insert (warnings, contraindications) — currently a Blocking data gap (DG001)
Confirmed drug mechanism-of-action documentation from DrugBank (DG002)
A direct phenylephrine-monotherapy trial or systematic review against a defined nasal cavity disease endpoint (current evidence is mostly indirect/comparator-based)
Confirmation of Finland marketing-authorization status, since none currently exists
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.